BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs

Reuters

Jan 12

Jan 12 (Reuters) - Moleculin Biotech Inc MBRX.O:

MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMS
MOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIES
MOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028

Source text: ID:nGNX8nsQ5g

Further company coverage: MBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602480665"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602480665\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602480665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602480665","market":"fut","top_or_hot":-1,"title":"BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> Inc <span>MBRX.O</span>:</p><ul><li><p>MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMS</p></li><li><p>MOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIES</p></li><li><p>MOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028</p></li></ul><p>Source text: <span>ID:nGNX8nsQ5g</span></p><p>Further company coverage: <span>MBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> Inc <span>MBRX.O</span>:</p><ul><li><p>MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMS</p></li><li><p>MOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIES</p></li><li><p>MOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028</p></li></ul><p>Source text: <span>ID:nGNX8nsQ5g</span></p><p>Further company coverage: <span>MBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBRX","symbol_name":"Moleculin Biotech, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA31DX7F:1","article_id":"2602480665","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602480665","pubTimestamp":1768225306,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical ProgramsJan 12 (Reuters) - Moleculin Bio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBRX":"Moleculin Biotech, Inc.","BK4139":"生物科技"},"translate_title":"简介-Moleculin加速了对2026年的展望，首个关键试验揭盲步入正轨、全球试验扩展以及多个外部/Iit资助的临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBRX":0.9},"content_text":"BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical ProgramsJan 12 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMSMOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIESMOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028Source text: ID:nGNX8nsQ5gFurther company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}